Alogliptin for type 2 diabetes
- Aust Prescr 2014;37:28-35
- 12 December 2013
- DOI: 10.18773/austprescr.2014.011
Some of the views expressed in the following notes on newly approved products should be regarded as preliminary, as there may have been limited published data at the time of publication, and little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. Before new drugs are prescribed, the Committee believes it is important that more detailed information is obtained from the manufacturer's approved product information, a drug information centre or some other appropriate source.
Approved indication: type 2 diabetes
6.25 mg, 12.5 mg and 25 mg tablets
Australian Medicines Handbook section 10.1.3
Alogliptin is the fifth dipeptidyl peptidase 4 (DPP4) inhibitor to be approved for diabetes in Australia, along with linagliptin (Aust Prescr 2012;35:70-1), saxagliptin (Aust Prescr 2011;34:89-91), vildagliptin (Aust Prescr 2010;33:89-95) and sitagliptin (Aust Prescr 2008;31:49-55).
DPP4 enzymes inactivate incretin hormones which are produced after a meal. These hormones promote insulin release and lower glucagon production which leads to lower serum glucose concentrations. By inhibiting DPP4 enzymes, the 'gliptins' prolong the effects of incretins and improve glycaemic control (Aust Prescr 2008;31:102-4 and 104-8).
Alogliptin's bioavailability is 100%. Following oral administration, peak plasma concentrations are reached after 1–2 hours. The drug is not extensively metabolised and clinically relevant pharmacokinetic drug interactions are not expected. Alogliptin has a terminal half-life of 21 hours and the majority of the dose (60–71%) is eliminated unchanged in the urine.
Alogliptin has been investigated in numerous randomised controlled trials in patients whose type 2 diabetes is not adequately managed with diet and exercise or other antidiabetic drugs. Some of these trials are listed in the Table.
|Trials||Treatment arms||Mean baseline HbA1c (%)||Mean change in HbA1c (%) from baseline|
|Alogliptin plus metformin1 for 26 weeks
|alogliptin 12.5 mg + metformin||7.9–8.0||-0.60|
|alogliptin 25 mg + metformin||-0.60|
|placebo + metformin||-0.10|
|Alogliptin plus a sulfonylurea2 for 26 weeks
|alogliptin 12.5 mg + glibenclamide||8.08||-0.39|
|alogliptin 25 mg + glibenclamide||8.09||-0.53|
|placebo + glibenclamide||8.15||+0.01|
|Alogliptin plus a thiazolidinedione3 (metformin or a sulfonylurea allowed) for 26 weeks
|alogliptin 12.5 mg + pioglitazone||8.1||-0.66|
|alogliptin 25 mg + pioglitazone||8.0||-0.80|
|placebo + pioglitazone||8.0||-0.19|
|Alogliptin plus insulin4 (with or without metformin) for 26 weeks
|alogliptin 12.5 mg + insulin||9.3||-0.63|
|alogliptin 25 mg + insulin||-0.71|
|placebo + insulin||-0.13|
|Alogliptin plus metformin and a thiazolidinedione5 for 52 weeks
|alogliptin 25 mg + metformin + pioglitazone 30 mg
||8.3||-0.89 at 26 weeks
-0.70 at 52 weeks
|placebo + metformin + pioglitazone 45 mg||8.1||-0.42 at 26 weeks
-0.29 at 52 weeks
|Monotherapy6 for 26 weeks
|alogliptin 12.5 mg||7.9||-0.56|
|alogliptin 25 mg||-0.59|
|Alogliptin plus a thiazolidinedione7 for 26 weeks
|alogliptin 12.5 mg + pioglitazone 30 mg||8.85||-1.56|
|alogliptin 25 mg + pioglitazone 30 mg||8.80||-1.71|
|alogliptin 25 mg||8.80||-0.96|
|pioglitazone 30 mg||8.76||-1.15|
Once-daily alogliptin was found to significantly reduce glycated haemoglobin (HbA1c) – a surrogate marker for glycaemic control – when added to stable doses of metformin,1 glibenclamide,2 pioglitazone3 or insulin (with or without metformin).4 HbA1c reductions were also seen when it was added to dual therapy with metformin and pioglitazone5 (see Table).
During trials, the most common adverse event with alogliptin was pruritus. Headache, diarrhoea, myalgia, rash, musculoskeletal pain, abdominal pain, nausea and infections (influenza, nasopharyngitis, upper respiratory tract infection) were also common (1–10% of patients).
Severe hypersensitivity reactions (e.g. angioedema, Stevens-Johnson syndrome), hepatic failure and pancreatitis have been reported in postmarketing surveillance. Alogliptin is not recommended in patients with severe hepatic impairment.
Hypoglycaemia can occur when alogliptin is added to insulin or a sulfonylurea so these drugs may need to be given at lower doses during combination therapy.
Alogliptin is a category B3 pregnancy drug. There are no data in humans so it is best avoided during pregnancy. Alogliptin was excreted in breast milk in animal studies so there is a risk of exposure to a breastfeeding infant.
Renal function should be assessed before patients start alogliptin. Dose reduction is recommended in patients with moderate (creatinine clearance 30 to 50 mL/min) or severe renal impairment (creatinine clearance <30 mL/min) and those with end-stage renal disease requiring dialysis. Experience in patients with severe renal disease is limited and caution is urged.
As with other DPP4 inhibitors, alogliptin is modestly effective at lowering HbA1c. It provides another option for monotherapy or as an add-on therapy when a patient's diabetes is not controlled by metformin, a sulfonylurea, a thiazolidinedione or insulin. It can also be added as a third option in patients already taking metformin and pioglitazone. Despite showing benefit in trials, alogliptin is currently not indicated for initial combination therapy in Australia.7
The Transparency Score () is explained in New drugs: transparency, Vol 37 No 1, Aust Prescr 2014;37:27.
At the time the comment was prepared, information about this drug was available on the web site of the Food and Drug Administration in the USA (www.fda.gov).
At the time the comment was prepared, a scientific discussion about this drug was available on the website of the European Medicines Agency (www.emea.europa.eu).